Mickael Hiligsmann
Overview
Explore the profile of Mickael Hiligsmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
246
Citations
2556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ecarnot F, Amuthavalli Thiyagarajan J, Barbagallo M, Barratt J, Constantinescu S, Elkayam O, et al.
Aging Clin Exp Res
. 2025 Feb;
37(1):46.
PMID: 39985736
Musculoskeletal disorders are a significant public health burden concern, projected to increase in the coming decades, and will substantially contribute to the rising prevalence of functional impairment, frailty and disability...
2.
Fuggle N, Laslop A, Rizzoli R, Al-Daghri N, Alokail M, Balkowiec-Iskra E, et al.
Drugs
. 2025 Feb;
85(3):343-360.
PMID: 39969778
Osteoporosis and osteoarthritis are key diseases of musculoskeletal ageing and are increasing in prevalence and burden with the progressively ageing population worldwide. These conditions are thus particularly common in 'the...
3.
Saadat P, Bansback N, Falahee M, Hiligsmann M, Tugwell P, Buchbinder R, et al.
BMJ Open
. 2025 Jan;
15(1):e088267.
PMID: 39819933
Introduction: The pharmacological management of inflammatory arthritis often requires choices that involve trade-offs between benefits, risks and other attributes such as administration route, frequency and cost. This living systematic review...
4.
Daccache C, Rizk R, Hiligsmann M, Evers S, Karam R
Expert Rev Pharmacoecon Outcomes Res
. 2025 Jan;
1-15.
PMID: 39772975
Background: Economic evaluation guidelines (EEGs) serve as a valuable tool to assist appraisers in making consistent and transparent recommendations, standardize EE studies, enhance their quality, and minimize methodological uncertainties. As...
5.
Kardas P, Bennett B, Borah B, Burnier M, Daly C, Hiligsmann M, et al.
Front Pharmacol
. 2025 Jan;
15:1444012.
PMID: 39764461
Background: Non-adherence to medication remains a persistent and significant challenge, with profound implications for patient outcomes and the long-term sustainability of healthcare systems. Two decades ago, the World Health Organization...
6.
Nagendra L, Chandran M, Reginster J, Bhadada S, Bhattacharya S, Dutta D, et al.
Osteoporos Int
. 2024 Dec;
36(2):311-322.
PMID: 39730734
Purpose: Osteoporosis represents a significant public health challenge in India, with an increasing economic burden due to the aging population. This study evaluated the cost-effectiveness of using fracture risk assessment...
7.
Li N, Majoie M, Evers S, Rijkers K, Gubler F, Rouhl R, et al.
J Med Econ
. 2024 Dec;
28(1):114-123.
PMID: 39686574
Objective: The objective of this study was to explore the financial consequences of adopting cenobamate as a treatment alternative in epilepsy patients with drug-resistant focal onset seizures (FOS) from a...
8.
Reginster J, Silverman S, Alokail M, Al-Daghri N, Hiligsmann M
JBMR Plus
. 2024 Dec;
9(1):ziae138.
PMID: 39664931
Radiofrequency echographic multi-spectrometry (REMS) is an innovative, non-ionizing diagnostic technique that has shown high accuracy and precision, making it a promising alternative to DXA for osteoporosis diagnosis in clinical settings....
9.
Germeni E, Fifer S, Hiligsmann M, Stein B, Tonkinson M, Joshi M, et al.
Int J Technol Assess Health Care
. 2024 Nov;
40(1):e60.
PMID: 39562326
Objectives: The roles and potential value of patient preference (PP) data in health technology assessment (HTA) remain to be fully realized despite an expanding literature and various efforts to establish...
10.
Schoonvelde S, Schoonvelde S, Wiethoff I, Wiethoff I, Zwetsloot P, Zwetsloot P, et al.
Eur Heart J Qual Care Clin Outcomes
. 2024 Nov;
11(2):174-185.
PMID: 39520534
Introduction: Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease. The impact of HCM on quality of life (QoL) and societal costs remains poorly understood. This prospective multi-centre burden...